{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:43:46Z","timestamp":1792165426650,"version":"4.4.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30-DK-089507"],"award-info":[{"award-number":["P30-DK-089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000423"],"award-info":[{"award-number":["UL1 TR000423"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["R565CR11"],"award-info":[{"award-number":["R565CR11"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SINGH15R0"],"award-info":[{"award-number":["SINGH15R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["VERKMA15R0"],"award-info":[{"award-number":["VERKMA15R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Cystic fibrosis\u2013related diabetes (CFRD) is a common complication of cystic fibrosis (CF), increasing patient morbidity and mortality. Poor understanding of CFRD pathogenesis limits the development of targeted therapies to treat and\/or prevent the disease. The aim of this study was to evaluate islet pathology, specifically, inflammation, amyloid deposition, and endocrine cell composition in subjects with CF with diabetes and with CF without diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A retrospective analysis of archived pancreas tissue collected at autopsy was conducted using pancreas tissue from subjects with CF and diabetes (CFRD) (n = 18) and CF without diabetes (CF-no DM) (n = 17). Two cohorts of control non-CF subjects were identified, each matched to CFRD and CF-no DM subjects for age, sex, and BMI (non-CF older, n = 20, and non-CF younger, n = 20), respectively. Immunohistochemistry was performed to assess interleukin-1\u03b2 (IL-1\u03b2) and islet hormone (insulin, glucagon, somatostatin, and pancreatic polypeptide) immunoreactivity; histochemistry was performed to quantify amyloid deposition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Islet IL-1\u03b2 immunoreactivity was substantially increased in both CFRD and CF-no DM subjects compared with non-CF subjects and was common in young subjects with CF (\u226410 years of age). In contrast, islet amyloid deposition was increased only in CFRD subjects. We also observe abnormal islet hormone immunoreactivity, characterized by increased glucagon immunoreactivity, in CF-no DM and CFRD subjects compared with non-CF subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>These findings reveal novel molecular pathways and therapeutic targets underlying islet pathology in CF subjects and may be important in developing new approaches to treat CFRD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-1387","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T01:30:28Z","timestamp":1517535028000},"page":"823-830","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":79,"title":["Islet Interleukin-1\u03b2 Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to \u03b2-Cell Failure"],"prefix":"10.2337","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-4087","authenticated-orcid":false,"given":"Rebecca L.","family":"Hull","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail H.","family":"Deutsch","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne L.","family":"Fligner","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Frevert","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA"},{"name":"Department of Comparative Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Sanda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA"},{"name":"Diabetes Center, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"2022031301472638700_B1","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301472638700_B2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"2022031301472638700_B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2213-8587(13)70015-9","article-title":"New insights into cystic fibrosis-related diabetes in children","volume":"1","author":"Ode","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301472638700_B4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2022031301472638700_B5","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301472638700_B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1651-2227.1993.tb12628.x","article-title":"Diabetes mellitus in cystic fibrosis: genetic and immunological markers","volume":"82","author":"Lanng","year":"1993","journal-title":"Acta Paediatr"},{"key":"2022031301472638700_B7","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/dc16-0020","article-title":"Does \u03b2-cell autoimmunity play a role in cystic fibrosis-related diabetes? Analysis based on the German\/Austrian Diabetes Patienten Verlaufsdokumentation Registry","volume":"39","author":"Konrad","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301472638700_B8","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/db13-0510","article-title":"Genetic modifiers of cystic fibrosis-related diabetes","volume":"62","author":"Blackman","year":"2013","journal-title":"Diabetes"},{"key":"2022031301472638700_B9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00125-009-1436-2","article-title":"A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis","volume":"52","author":"Blackman","year":"2009","journal-title":"Diabetologia"},{"key":"2022031301472638700_B10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1756-0500-5-561","article-title":"Association between the IVS4G&gt;T mutation in the TCF7L2 gene and susceptibility to diabetes in cystic fibrosis patients","volume":"5","author":"Furgeri","year":"2012","journal-title":"BMC Res Notes"},{"key":"2022031301472638700_B11","first-page":"80","article-title":"Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis","volume":"79","author":"Austin","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301472638700_B12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2007.05.012","article-title":"Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes","volume":"151","author":"Elder","year":"2007","journal-title":"J Pediatr"},{"key":"2022031301472638700_B13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2265.1994.tb02533.x","article-title":"Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance","volume":"41","author":"Lanng","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2022031301472638700_B14","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1172\/JCI60610","article-title":"Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets","volume":"122","author":"Olivier","year":"2012","journal-title":"J Clin Invest"},{"key":"2022031301472638700_B15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.1163600","article-title":"Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs","volume":"321","author":"Rogers","year":"2008","journal-title":"Science"},{"key":"2022031301472638700_B16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/CS20140059","article-title":"Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass","volume":"128","author":"Uc","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"2022031301472638700_B17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/15513818609025923","article-title":"Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies","volume":"6","author":"Soejima","year":"1986","journal-title":"Pediatr Pathol"},{"key":"2022031301472638700_B18","first-page":"602","article-title":"Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study","volume":"110","author":"Abdul-Karim","year":"1986","journal-title":"Arch Pathol Lab Med"},{"key":"2022031301472638700_B19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: an immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"2022031301472638700_B20","first-page":"1267","article-title":"Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis","volume":"81","author":"Couce","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301472638700_B21","first-page":"151","article-title":"Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes","volume":"9","author":"Clark","year":"1988","journal-title":"Diabetes Res"},{"key":"2022031301472638700_B22","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u03b2-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens","year":"2011","journal-title":"Am J Pathol"},{"key":"2022031301472638700_B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/03009734000000014","article-title":"Quantitative studies on amyloid in the islets of Langerhans","volume":"77","author":"Westermark","year":"1972","journal-title":"Ups J Med Sci"},{"key":"2022031301472638700_B24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"2022031301472638700_B25","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.4049\/jimmunol.1002854","article-title":"IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction","volume":"187","author":"Westwell-Roper","year":"2011","journal-title":"J Immunol"},{"key":"2022031301472638700_B26","doi-asserted-by":"crossref","first-page":"e0120912","DOI":"10.1371\/journal.pone.0120912","article-title":"High peripheral blood th17 percent associated with poor lung function in cystic fibrosis","volume":"10","author":"Mulcahy","year":"2015","journal-title":"PLoS One"},{"key":"2022031301472638700_B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201102-0236OC","article-title":"The Th17 pathway in cystic fibrosis lung disease","volume":"184","author":"Tan","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2022031301472638700_B28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201206-1150OC","article-title":"A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection","volume":"187","author":"Tiringer","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2022031301472638700_B29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00125-012-2808-6","article-title":"Loss of coupling between calcium influx, energy consumption and insulin secretion associated with development of hyperglycaemia in the UCD-T2DM rat model of type 2 diabetes","volume":"56","author":"Rountree","year":"2013","journal-title":"Diabetologia"},{"key":"2022031301472638700_B30","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0305683101","article-title":"Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets","volume":"101","author":"Maedler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031301472638700_B31","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/diabetes.54.suppl_2.S97","article-title":"Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities","volume":"54","author":"Cnop","year":"2005","journal-title":"Diabetes"},{"key":"2022031301472638700_B32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"2022031301472638700_B33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1259\/bjr\/24009651","article-title":"MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients","volume":"83","author":"Sequeiros","year":"2010","journal-title":"Br J Radiol"},{"key":"2022031301472638700_B34","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cell.2012.07.029","article-title":"Pancreatic \u03b2 cell dedifferentiation as a mechanism of diabetic \u03b2 cell failure","volume":"150","author":"Talchai","year":"2012","journal-title":"Cell"},{"key":"2022031301472638700_B35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(05)80032-0","article-title":"Pancreatic endocrine function in cystic fibrosis","volume":"118","author":"Moran","year":"1991","journal-title":"J Pediatr"},{"key":"2022031301472638700_B36","first-page":"69","article-title":"Postprandial hyperglycemia and pancreatic function in cystic fibrosis patients","volume":"18","author":"Hinds","year":"1991","journal-title":"Diabetes Res"},{"key":"2022031301472638700_B37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41598-017-00098-8","article-title":"CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells","volume":"7","author":"Edlund","year":"2017","journal-title":"Sci Rep"},{"key":"2022031301472638700_B38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tcb.2014.12.009","article-title":"Mechanisms of inflammasome activation: recent advances and novel insights","volume":"25","author":"Vanaja","year":"2015","journal-title":"Trends Cell Biol"},{"key":"2022031301472638700_B39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"2022031301472638700_B40","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1210\/jc.2008-0396","article-title":"Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation","volume":"93","author":"B\u00f6ni-Schnetzler","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-1387","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/4\/823\/550871\/dc171387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/4\/823\/550871\/dc171387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:47:01Z","timestamp":1647150421000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/4\/823\/36869\/Islet-Interleukin-1-Immunoreactivity-Is-an-Early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,2,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-1387","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]}}}